Huibiao Quan1, Huachuan Zhang2, Weiping Wei3, Tuanyu Fang3. 1. Department of Endocrinology, People's Hospital of Hainan Province, Haikou, Hainan 570311, China. Electronic address: quanhuibiao_2015@163.com. 2. Endocrine Laboratory, People's Hospital of Hainan Province, Haikou, Hainan 570311, China. 3. Department of Endocrinology, People's Hospital of Hainan Province, Haikou, Hainan 570311, China.
Abstract
BACKGROUND: Although men and women have similar diabetes prevalence, the same medicine will cause different therapeutic results in different genders. To understand the molecular mechanism, we explored the effects of a combined therapy of Exenatide and Metformin on obesity and overweight female and male patients with newly diagnosed type 2 diabetes mellitus (T2DM). METHODS:One hundred and five overweight and obesity patients with newly diagnosed T2DM (n=54 female in a female group and n=51 males in a male group) received the therapy: 5 μg Exenatide+0.5 g MET twice daily for 4 weeks, then 10 μg Exenatide+0.5 g MET twice daily for 24 weeks. RESULTS: There was an average of 8.2 ± 2.4 kg and 4.6 ± 2.3 kg weight loss in female and male patients, respectively. The combined therapy showed better effects on female than male patients for improving insulin sensitivity and serum lipid profile, reducing insulin resistance, increasing adiponectin levels, and decreasing the levels of HbA1c, BMI, resistin, TNF-alpha and C-reactive protein (P<0.05). CONCLUSIONS: The combined therapy of Exenatide and MET shows better therapeutic results in female patients than in male patients. Therefore, the dual therapy is more suitable for female patients.
RCT Entities:
BACKGROUND: Although men and women have similar diabetes prevalence, the same medicine will cause different therapeutic results in different genders. To understand the molecular mechanism, we explored the effects of a combined therapy of Exenatide and Metformin on obesity and overweight female and male patients with newly diagnosed type 2 diabetes mellitus (T2DM). METHODS: One hundred and five overweight and obesitypatients with newly diagnosed T2DM (n=54 female in a female group and n=51 males in a male group) received the therapy: 5 μg Exenatide+0.5 g MET twice daily for 4 weeks, then 10 μg Exenatide+0.5 g MET twice daily for 24 weeks. RESULTS: There was an average of 8.2 ± 2.4 kg and 4.6 ± 2.3 kg weight loss in female and male patients, respectively. The combined therapy showed better effects on female than male patients for improving insulin sensitivity and serum lipid profile, reducing insulin resistance, increasing adiponectin levels, and decreasing the levels of HbA1c, BMI, resistin, TNF-alpha and C-reactive protein (P<0.05). CONCLUSIONS: The combined therapy of Exenatide and MET shows better therapeutic results in female patients than in male patients. Therefore, the dual therapy is more suitable for female patients.
Authors: Dmitry A Goncharov; Elena A Goncharova; Stevan P Tofovic; Jian Hu; Jeff J Baust; Andressa Z Pena; Arnab Ray; Analise Rode; Rebecca R Vanderpool; Ana L Mora; Mark T Gladwin; Yen-Chun Lai Journal: Am J Respir Crit Care Med Date: 2018-09-01 Impact factor: 21.405
Authors: Isabelle Côté; Sara M Green; Joshua F Yarrow; Christine F Conover; Hale Z Toklu; Drake Morgan; Christy S Carter; Nihal Tümer; Philip J Scarpace Journal: J Neuroendocrinol Date: 2018-11 Impact factor: 3.627
Authors: Carolyn T Bramante; Nicholas E Ingraham; Thomas A Murray; Schelomo Marmor; Shane Hovertsen; Jessica Gronski; Chace McNeil; Ruoying Feng; Gabriel Guzman; Nermine Abdelwahab; Samantha King; Thomas Meehan; Kathryn M Pendleton; Bradley Benson; Deneen Vojta; Christopher J Tignanelli Journal: medRxiv Date: 2020-06-28
Authors: Gilmar Reis; Eduardo Augusto Dos Santos Moreira Silva; Daniela Carla Medeiros Silva; Lehana Thabane; Aline Cruz Milagres; Thiago Santiago Ferreira; Castilho Vitor Quirino Dos Santos; Adhemar Dias de Figueiredo Neto; Eduardo Diniz Callegari; Leonardo Cançado Monteiro Savassi; Maria Izabel Campos Simplicio; Luciene Barra Ribeiro; Rosemary Oliveira; Ofir Harari; Holly Bailey; Jamie I Forrest; Alla Glushchenko; Sheila Sprague; Paula McKay; Craig R Rayner; Hinda Ruton; Gordon H Guyatt; Edward J Mills Journal: Lancet Reg Health Am Date: 2021-12-14
Authors: Sherehan Ibrahim; Jamie R Lowe; Carolyn T Bramante; Surbhi Shah; Nichole R Klatt; Nancy Sherwood; Louis Aronne; Michael Puskarich; Leonardo Tamariz; Ana Palacio; Eric Bomberg; Michael Usher; Samantha King; Brad Benson; Deneen Vojta; Chris Tignanelli; Nicholas Ingraham Journal: Front Endocrinol (Lausanne) Date: 2021-07-22 Impact factor: 5.555